Request Trial
shutterstock_1595586766_ken_wolter
Ken Wolter / Shutterstock.com
6 March 2020Big PharmaClaire Irvine

Broad Institute down (but not out) in the European fight over CRISPR IP

Following the upholding in January 2020 of the revocation of the Broad Institute’s lead European patent (EP 2771468) by a European Patent Office (EPO) Appeal Board, there has been speculation that the University of California and its co-applicants (UC) have the upper hand in the European fight over the IP of clustered regularly interspaced short palindromic repeats (more commonly known as ‘CRISPR’), the latest incarnation of genome editing and deliberate alteration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
Report reveals surge of AI adoption in IP but lawyers remain cautious
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
Sun Pharma and BMS lead 2025 ANDA litigation
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.


Editor's picks

Deadline extended: Who are the world’s best in-house counsel?
Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026

Editor's picks

Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026

More features

From migraine drugs to COVID vaccine spats, US lawsuits pile up
How AI will be shaped by legal and regulatory developments in 2026
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
Arnold & Porter loses another regulatory partner to growing rival
CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’
Novo Nordisk secures China win ahead of key patent expiration
Edwards v Meril: Inside the UPC’s landmark medtech showdown
Bird & Bird targets Nordic life sciences growth with regulatory hire